Efficacy of PegInterferon-Ribavirin-Boceprevir Therapy in Patients Infected With G1 HCV With Cirrhosis, Awaiting Liver Transplantation

Inclusion Criteria: * Adult 18 years and older * Chronic infection with hepatitis C virus proven with positive PCR for more than 6 months * Viral genotype 1 * Cirrhosis while awaiting liver transplantation * MELD score \< or equal to 18 * With or without hepatocellular carcinoma * Naive to antiviral C treatment * Failure on a previous treatment. Failure is defined as the persistence of detectable HCV RNA. The previous HCV failure treatment profile must be able to be documented according to the following terminology:- Relapsing patient: HCV RNA undetectable at the end of treatment, becoming detectable again after the discontinuation of treatment- Breakthrough: increase of viremia of 1 log or more during the treatment - Non-responding patient with partial response: HCV RNA detectable at W24 without ever having been undetectable and with a decrease in HCV RNA ≥ 2 log at W12 - Non-responding patient with nul response: decrease in HCV RNA \< 2 log at W12 * No need for prior treatment wash-out * Negative pregnancy test in women of child-bearing age * Double method of contraception in men and women of child-bearing age during the entire duration of treatment and the 6 months following its discontinuation * Free, informed, and written consent (signed on the day of pre-enrollment at the latest and before all exams required by the study) * Person enrolled in or a beneficiary of a social security/Universal Health Insurance Coverage * Inclusion approved by the Decision Support Committee…